Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

09:00am - American Society of Clinical Oncology Meeting - Abstract No #3503

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.09 USD

Average target price

53.19 USD

Spread / Average Target

+29.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-19.85%	83.29B
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:03 2024-05-31 EDT			5-day change	1st Jan Change
41.12 ^USD	+2.17%		-0.28%	-19.85%

05-30	Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	MT
05-30	Bristol Myers: FDA approval for Breyanzi	CF

Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	05-30	MT
Bristol Myers: FDA approval for Breyanzi	05-30	CF
US FDA allows use of Bristol's cell therapy for rare blood cancer	05-30	RE
U.S. Food and Drug Administration Approves Bristol Myers Squibb?s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma	05-30	CI
Bristol Myers Squibb’s Urothelial Carcinoma Combo Drug Gets EU Commission Approval	05-29	MT
Bristol-Myers Squibb Gains EU Approval for Opdivo Combination Therapy for Urothelial Cancer	05-29	MT
Bristol Myers: new EC approval for Opdivo	05-29	CF
Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination with Cisplatin and Gemcitabine	05-29	CI
Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License	05-28	MT
Bristol Myers: will present data on schizophrenia	05-27	CF
Bristol Myers: presents over 130 studies at ASCO	05-27	CF
Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment	05-23	MT
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million	05-22	RE
Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines	05-22	MT
Bristol Myers: 10-year strategy for poor countries	05-22	CF
Bristol-Myers Squibb Invests in NeoPhore	05-22	MT
Neophore Limited announced that it has received funding from a group of investors	05-21	CI
Bristol Myers: national schizophrenia campaign	05-21	CF
Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab	05-21	MT
Bristol Myers: deadline set for subcutaneous Opdivo	05-21	CF
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (Nivolumab and Hyaluronidase)	05-21	CI
Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis	05-16	CI
Everlasting momentum	05-16
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma	05-16	DJ
Bristol-Myers Squibb Gets FDA Accelerated Approval for Breyanzi for Follicular Lymphoma	05-16	MT